Telix Pharmaceuticals to host neuro-oncology portfolio webinar
Telix Pharmaceuticals Limited announced an educational webinar focusing on unmet needs in neurologic oncology and the potential role of theranostics. The event features a clinical update by David N. Cade, MD, and a fireside chat with medical experts from UMC Utrecht and Kepler University Hospital Linz. The webinar is scheduled for June 29, 2026, at 5:00 p.m. EDT.
*this image is generated using AI for illustrative purposes only.
Telix Pharmaceuticals Limited announced it will host an educational webinar to discuss unmet needs in neurologic oncology, specifically glioma and glioblastoma, and how theranostics may address these challenges. The event aims to provide physician perspectives on future therapeutic directions within the company's Neuro-Oncology Portfolio.
David N. Cade, MD, Telix Group Chief Medical Officer, will deliver a clinical update. Following the presentation, a fireside chat will feature Nelleke Tolboom, MD, a Nuclear Medicine physician and academic faculty member at UMC Utrecht in the Netherlands, and Josef Pichler, MD, Head of the Neuro-oncological Center at Kepler University Hospital Linz in Austria.
The session will conclude with a question-and-answer segment involving Dr. Cade and Richard Valeix, CEO of Telix Therapeutics. Participants can register for the event through the provided link.
Webinar Details
| Event | Date | Time |
|---|---|---|
| Webinar (EDT) | Monday June 29, 2026 | 5:00 p.m. |
| Webinar (AEST) | Tuesday June 30, 2026 | 7:00 a.m. |
Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals to address unmet medical need in oncology and rare diseases. The company is headquartered in Melbourne, Australia, with international operations across the United States, United Kingdom, Brazil, Canada, Europe, and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).
What specific advancements in theranostics for glioma and glioblastoma are expected to be highlighted during the webinar?
How might the insights from the physician panel influence Telix's future clinical trial designs or regulatory strategies?
What are the potential market impacts if Telix successfully addresses unmet needs in neurologic oncology with its theranostics approach?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
